Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Daniel Colodenco, Oscar Palomares, Carlos Celis, Alan Kaplan & Christian Domingo. (2018) Moving toward consensus on diagnosis and management of severe asthma in adults. Current Medical Research and Opinion 34:3, pages 387-399.
Read now
Read now
Jefferson Russo Victor. (2017) Allergen-specific IgG as a mediator of allergy inhibition: Lessons from mother to child. Human Vaccines & Immunotherapeutics 13:3, pages 507-513.
Read now
Read now
Articles from other publishers (18)
Thomas B. Casale, Bradley E. Chipps, Ahmar Iqbal, Bongin Yoo, Lauren A. Millette & Nicola A. Hanania. (2023) Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab. The Journal of Allergy and Clinical Immunology: In Practice.
Crossref
Crossref
Nicola A. Hanania, Robert Niven, Pascal Chanez, Deschildre Antoine, Pascal Pfister, Lorena Garcia Conde & Xavier Jaumont. (2022) Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organization Journal 15:10, pages 100695.
Crossref
Crossref
Aşkın Gülşen. 2022. Recent Advances in Asthma Research and Treatments. Recent Advances in Asthma Research and Treatments.
Polliana Mihaela Leru & Vlad Florin Anton. (2021) Real-Life Benefit of Omalizumab in Improving Control of Bronchial Asthma During COVID-19 Pandemic. Cureus.
Crossref
Crossref
Flenches Catalina, Lupusor Eugeniu & Budin Corina. (2021) Is the allergic reaction to Aspergillus a contraindication for biological therapy in severe asthma?. Pneumologia 70:1, pages 55-58.
Crossref
Crossref
Tomohiro Akaba, Mitsuko Kondo, Fumi Kobayashi, Nahoko Honda, Soshi Muramatsu, Osamitsu Yagi, Kiyoshi Takeyama, Yukako Seo, Manabu Nonaka & Etsuko Tagaya. (2021) Characteristics of patients with severe asthma who experienced treatment failure with omalizumab. Pulmonary Pharmacology & Therapeutics 68, pages 102032.
Crossref
Crossref
Ian D. Pavord, Andrew Menzies-Gow, Roland Buhl, Pascal Chanez, Mark Dransfield, Njira Lugogo, Oliver N. Keene, Eric S. Bradford & Steve W. Yancey. (2021) Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. The Journal of Allergy and Clinical Immunology: In Practice 9:3, pages 1121-1132.e7.
Crossref
Crossref
Chad R. Marion, Manuel Izquierdo, Holly C. Hanes & Christopher Barrios. (2021) Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome. Current Allergy and Asthma Reports 21:2.
Crossref
Crossref
Saraid Cerda-Reyes, Juan Gabriel Maldonado-Hernández, Rosa Isela Campos-Gutiérrez, Nidia Karen Castillón-Benavides & Armando Partida-Gaytán. (2021) Reporte de dos casos clínicos de adolescentes con asma grave eosinofílica refractaria no controlada tratados con mepolizumab a un año de seguimiento. Alergia, Asma e Inmunología Pediátricas 30:3, pages 104-109.
Crossref
Crossref
Abdulrahman Alzahrani, Aamir Hussain, Fahad Alhadian, Jameel Hakeem, Sana Douaoui, Omar Tliba, Peter Bradding & Yassine Amrani. 2021. Lung Inflammation in Health and Disease, Volume I. Lung Inflammation in Health and Disease, Volume I
1
12
.
Michael C Peters & Sally E Wenzel. (2020) Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. The Lancet 395:10221, pages 371-383.
Crossref
Crossref
Jakub Novosad & Irena Krčmová. (2020) Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?. International Journal of Immunopathology and Pharmacology 34, pages 205873842094238.
Crossref
Crossref
Irena Krčmová, Jakub Novosad, Eva Malá & Jan Krejsek. (2018) Small, Prospective, Observational, Pilot Study in Patients with Severe Asthma after Discontinuation of Omalizumab Treatment. Clinical Therapeutics 40:11, pages 1942-1953.
Crossref
Crossref
K.L. Winthrop, X. Mariette, J.T. Silva, E. Benamu, L.H. Calabrese, A. Dumusc, J.S. Smolen, J.M. Aguado & M. Fernández-Ruiz. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clinical Microbiology and Infection 24, pages S21-S40.
Crossref
Crossref
Arzu Yorgancıoğlu, Ferda Öner Erkekol, Dilşad Mungan, Münevver Erdinç, Bilun Gemicioğlu, Zeynep Ferhan Özşeker, Papatya Bayrak Değirmenci , Sibel Naycı, Aykut Çilli, Füsun Erdenen, Cengiz Kırmaz, Dane Ediger, Arzu Didem Yalçın, Suna Büyüköztürk, Sami Öztürk, Mustafa Güleç, Sacide Rana Işık, Ali Fuat Kalyoncu, Özlem Göksel, Ömür Aydın, Yavuz Havlucu, İdilhan Baloğlu Ar & Ahmet Erdoğdu. (2018) Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial. International Archives of Allergy and Immunology 176:3-4, pages 225-233.
Crossref
Crossref
Derek G. Waller & Anthony P. Sampson. 2018. Medical Pharmacology and Therapeutics. Medical Pharmacology and Therapeutics
193
209
.
Cameron H. Flayer, Sarah S. Killingbeck, Erik Larson, Zoulfia Allakhverdi & Angela Haczku. 2018. Immunopharmacology and Inflammation. Immunopharmacology and Inflammation
57
84
.
Steven W. Yancey, Oliver N. Keene, Frank C. Albers, Hector Ortega, Stewart Bates, Eugene R. Bleecker & Ian Pavord. (2017) Biomarkers for severe eosinophilic asthma. Journal of Allergy and Clinical Immunology 140:6, pages 1509-1518.
Crossref
Crossref